Evidence map›Paper›PMID 34254473›Full record

ArticleJournal of Korean medical science2021

Incidence and Risk of Venous Thromboembolism in Bisphosphonates and Selective Estrogen Receptor Modulators Treatment in Korea.

So Young Park, Se Hwa Kim, Tae Young Kim, Young Kyun Lee, Yong Chan Ha, Sunmee Jang, Seong Hee Ahn, Ha Young Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Korean medical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. From Bone Health to Lifespan: Pleiotropic Effects of Antiresorptive Agents.Endocrinology and metabolism (Seoul, Korea) · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

So Young ParkDepartment of Endocrinology and Metabolism, Kyung Hee University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0002-4820-9415
Se Hwa KimDepartment of Internal Medicine, Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Incheon, Korea.ORCID https://orcid.org/0000-0003-2452-8419
Tae Young KimDepartment of Orthopaedic Surgery, School of Medicine, Konkuk University, Seoul, Korea.ORCID https://orcid.org/0000-0003-2028-0460
Young Kyun LeeDepartment of Orthopaedic Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.ORCID https://orcid.org/0000-0001-6564-4294
Yong Chan HaDepartment of Orthopaedic Surgery, College of Medicine, Chung-Ang University, Seoul, Korea.ORCID https://orcid.org/0000-0002-6249-0581
Sunmee JangCollege of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, Korea.ORCID https://orcid.org/0000-0002-8771-8693
Seong Hee AhnDivision of Endocrinology and Metabolism, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea.ORCID https://orcid.org/0000-0003-2558-2118
Ha Young KimDepartment of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea. hykimmd@hanmail.net.ORCID https://orcid.org/0000-0002-0651-2213
Ulsan College · KRChung-Ang University · KRGachon University · KRInha University Hospital · KRKonkuk University · KRKyung Hee University Dental Hospital · KRSeoul National University Bundang Hospital · KR

Funding

Korean Society for Bone and Mineral Research
6 · The paper itself

Abstract

backgroundSelective estrogen receptor modulators (SERMs) were associated with an increased risk of venous thromboembolism (VTE) due to the estrogen effect. In this study, we investigated the effect of SERMs on VTE compared to bisphosphonates (BPs) using the Korean National Health Insurance claims database.

methodsThis was a retrospective cohort study. Women over 50 years old who were first prescribed BPs or SERMs for osteoporosis treatment in 2012 were included. The difference in VTE incidence between the SERMs and BP groups was compared. Both groups were followed up for VTE or PE occurrence, death, or until December 2016. The study population was analyzed by 3:1 matching according to age using a multivariate Cox model.

resultsThe hazard ratio (HR) for VTE was 0.72 (95% confidence interval [CI], 0.40-1.28) in the SERMs group compared to BP group. Older age (60-69 vs. 50-59 years: HR, 3.77; 95% CI, 2.07-6.86 and 70-79 vs. 50-59 years: HR, 5.88; 95% CI, 3.14-11.02), major osteoporotic fracture (HR, 1.77; 95% CI, 1.16- 2.70), atrial fibrillation (HR, 3.31; 95% CI, 1.35-8.11), and estrogen replacement (HR, 3.40; 95% CI, 2.01-5.73) all increased VTE risk. In subgroup analysis of the SERMs group, past hospitalization (HR, 2.24; 95% CI, 1.02-4.92), estrogen replacement (HR, 5.75; 95% CI, 2.29-14.39), and glucocorticoid replacement (HR, 2.71; 95% CI, 1.05-7.0) increased VTE risk.

conclusionSERMs did not increase the risk of VTE compared to BPs in Koreans with osteoporosis. However, old age and estrogen replacement both increased VTE risk.

Indexed as

AgedAged, 80 and overBone Density Conservation AgentsDiphosphonatesHumansIncidenceMiddle AgedOsteoporosisRepublic of KoreaSelective Estrogen Receptor ModulatorsVenous ThromboembolismBone Density Conservation AgentsDiphosphonatesSelective Estrogen Receptor ModulatorsBisphosphonateOsteoporosisSelective Estrogen Receptor ModulatorsVenous Thromboembolism

Identifiers

PMID34254473
PMCPMC8275462
OpenAlexW3175438661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.